III.J.01. Shigella Vaccines. By FY96, determine molecular features required for protective immunity against Shigella species. By FY97, select the best methodology for vaccine development. By FY97, transition to advanced development a candidate Shigella sonnei vaccine to protect 80 percent of immunized troops from dysentery caused by S. sonnei. By FY99, transition to advanced development a candidate S. flexneri vaccine to protect 80 percent of immunized troops from dysentery caused by S. flexneri in deployed forces worldwide.
Supports: Army Modernization Plan, Medical Annex OProject, Sustain, and Protect the Force. The Medical Threat Facing a Force Projection Army (1994). Food and Drug Administration regulatory requirements.
|STO Manager:||TSO:||TRADOC POC:|
|COL W. H. Bancroft||MAJ Mark Seymour||Herbert Russakoff|
|MRMC||SARD-TM||CSS Battle Lab|